This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Medlab Clinical Crescita futura

Future criteri di controllo 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Medlab Clinical.

Informazioni chiave

-44.7%

Tasso di crescita degli utili

-44.7%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	15.0%
Tasso di crescita dei ricavi	41.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	04 May 2023

Aggiornamenti recenti sulla crescita futura

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Nov 22

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Previsioni di crescita degli utili e dei ricavi

ASX:MDC - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	4	-22	N/A	N/A	1
6/30/2023	7	-14	N/A	N/A	1
6/30/2022	2	-8	-9	-9	N/A
3/31/2022	1	-9	-10	-10	N/A
12/31/2021	4	-12	-11	-11	N/A
9/30/2021	4	-12	-11	-11	N/A
6/30/2021	1	-10	-10	-10	N/A
3/31/2021	1	-10	-9	-9	N/A
12/31/2020	1	-11	-8	-8	N/A
9/30/2020	2	-12	-10	-9	N/A
6/30/2020	3	-13	-11	-10	N/A
3/31/2020	4	-12	-11	-11	N/A
12/31/2019	4	-12	-12	-12	N/A
9/30/2019	5	-10	-11	-11	N/A
6/30/2019	5	-8	-11	-10	N/A
3/31/2019	5	-7	-9	-9	N/A
12/31/2018	5	-6	-7	-7	N/A
9/30/2018	4	-5	-6	-6	N/A
6/30/2018	4	-5	-5	-5	N/A
3/31/2018	4	-4	-5	-5	N/A
12/31/2017	5	-4	-5	-5	N/A
9/30/2017	5	-4	-4	-4	N/A
6/30/2017	4	-4	-4	-4	N/A
3/31/2017	4	-4	-4	-4	N/A
12/31/2016	4	-4	-4	-4	N/A
9/30/2016	3	-4	-4	-4	N/A
6/30/2016	3	-3	-4	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: MDC is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: MDC is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: MDC is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: MDC's revenue (41.7% per year) is forecast to grow faster than the Australian market (4.8% per year).

Ricavi ad alta crescita: MDC's revenue (41.7% per year) is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Medlab Clinical Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita